11 results about "Factor XII" patented technology

RNA interference agents for inhibiting the expression of Factor XII (FXII) gene are described. Pharmaceutical compositions comprising one or more FXII RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo are also described. Delivery of the FXII RNAi agent(s) to liver cells in vivo provides for inhibition of FXII gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with specificity to a clotting factor, such as Factor XII (FXII). A single dose of the monoclonal antibody is sufficient to enable a therapeutic effect of the PEPD.

The present invention provides monoclonal antibodies that bind to Factor XII (FXII) proteins and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to FXII and an activated form of FXII (FXIIa). In some embodiments, the antibodies of the invention may be used to inhibit or neutralize the activity of FXII, thereby providing a means for the treatment or prevention of diseases, disorders or conditions associated with thrombosis in humans.

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and / or a contact activation pathway-associated disorder.

The present disclosure describes cyclic peptide modulators of Factor XII(FXII) -uPAR signalling. Also described are pharmaceutical compositions comprising the cyclic peptides and their use in treating conditions, diseases and / or disorders responsive to FXII-uPAR modulation, including carcinoma, ovarian cancer, venous thromboembolisms and wound healing.

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.

The present application relates to a liquid formulation comprising at least 100 mg / ml of a protein comprising an antigen-binding domain that binds to FXII (and / or its activated form), an organic acid buffer, a non-ionic surfactant, and an amino acid stabilizer, wherein the formulation has a pH of 5.0-6.5 and a viscosity of less than 30 mPa*s at 20° C. An exemplary formulation comprises the specific factor XII antibody 3F7 in a formulation comprising a histidine buffer, a polysorbate 80 surfactant, and the amino acid stabilizers arginine and proline.

The present application is directed to a liquid formulation comprising at least 100mg / ml of a protein comprising an antigen binding domain that binds to FXII (and / or an activated form thereof), an organic buffer, a non-ionic surfactant and an amino acid stabilizer, wherein the pH of the formulation is 5.0-6.5 and the viscosity is less than 30 mPa*s at 20°C. Exemplary formulations comprise the specific Factor XII antibody 3F7, in formulation with a histidine buffer, a polysorbate 80 surfactant and the amino acid stabilizers arginine and proline.